Sinopharm’s coronavirus vaccine taken by about a million people

Henrietta Strickland
November 20, 2020

COVID-19 poses the greatest risk for older adults and people with preexisting health conditions.

"We're already suffering more than other community, and we would hate to see that suffering gap widen because members of our community did not affect to receive a vaccine that could have prevented kidney disease, prevented lung damage from COVID-19", Dr. Leon McDougle, the president of the National Medical Association said.

The Phase II trial reported in The Lancet involved a total of 560 healthy volunteers, with 160 aged 18-55, 160 aged 56-69, and 240 aged 70 or over.

Whether CoronaVac actually prevents people catching the coronavirus is now being assessed in phase 3 studies in Brazil, Indonesia and Turkey, along with the closely watched T-cell response triggered by the vaccine.

Previously, experts have raised concerns that a potential vaccine against COVID-19 may not be as effective in the older population, as the elderly are likely to have a weaker immune system compared to younger people. "We hope that this means our vaccine will help protect some of the most vulnerable people in society", Ramasamy said, but he noted that further research still needs to be conducted.

The virus is "having a field day", he told a University of Oxford and Blavatnik School of Government briefing on the global race for a Covid-19 vaccine.

ChAdOx1 nCov-2019 vaccine is now undergoing its Phase 3 trial with 40,051 participants now enrolled.

The ChAdOx1 nCoV-19 vaccine was developed as a replication-defective chimpanzee adenovirus-vectored vaccine expressing the full-length SARS-CoV-2 spike glycoprotein gene. Instead, it looked at safety indicators and the body's immune response.

Study recruitment occurred during a national lockdown in the United Kingdom when vulnerable individuals were advised to self-isolate.

Volunteers got two doses of the vaccine or a placebo, and no serious side effects related to the AZD1222 vaccine were reported, the researchers said. Responses were "similar" across all age groups, the researchers said.

The study's participants in the oldest age group had an average age of 73 to 74 and few had underlying health conditions, so the older age bracket was excluded as were those living in residential care homes.

In addition, nearly all participants of all ages were white and non-smokers. Immunogenicity was also similar across age groups after a boost vaccination. "Older adults (across the full spectrum of frailty) and those who care about them are eagerly awaiting this progress towards safe and effective COVID-19 vaccines". At one month after giving two doses of the vaccine, all age groups showed a similar level of antibody response.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER